Astria Therapeutics (NASDAQ:ATXS) Stock Passes Above Fifty Day Moving Average - Should You Sell?

Key Points

• Astria Therapeutics stock (NASDAQ:ATXS) crossed above its 50-day moving average of $7.99 and last traded at $12.38, indicating positive price momentum.
• Analysts have varied opinions on ATXS, with a consensus rating of "Hold" and target price of $25.00, while individual assessments range from "sell" to "overweight."
• The company reported an earnings per share (EPS) of ($0.57), beating the consensus estimate, and is focused on therapeutics for allergic and immunological diseases with its lead candidate in clinical trials.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $7.99 and traded as high as $12.38. Astria Therapeutics shares last traded at $12.38, with a volume of 1,429,504 shares changing hands.

Analysts Set New Price Targets

ATXS has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $49.00 price target on shares of Astria Therapeutics in a research note on Wednesday, September 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Astria Therapeutics in a research note on Wednesday, October 8th. Oppenheimer downgraded shares of Astria Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Tuesday, October 14th. HC Wainwright lowered shares of Astria Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, October 16th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. Three investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $25.00.

Astria Therapeutics Stock Up 1.4%

The stock has a market capitalization of $698.73 million, a PE ratio of -6.16 and a beta of 0.43. The firm's fifty day moving average price is $7.99 and its two-hundred day moving average price is $6.28.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.04. As a group, analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Institutional Trading of Astria Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in Astria Therapeutics by 185.8% in the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 3,557 shares during the period. Brooklyn Investment Group increased its position in shares of Astria Therapeutics by 1,079.6% during the 1st quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company's stock valued at $46,000 after purchasing an additional 7,957 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Astria Therapeutics by 1,127.4% in the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 7,971 shares during the period. Corton Capital Inc. bought a new position in shares of Astria Therapeutics in the 1st quarter worth approximately $72,000. Finally, AlphaQuest LLC boosted its holdings in shares of Astria Therapeutics by 100.9% in the first quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company's stock worth $76,000 after buying an additional 7,139 shares during the last quarter. Hedge funds and other institutional investors own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.